Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma
- 1 April 2002
- journal article
- review article
- Published by Elsevier BV in Seminars in Oncology
- Vol. 29 (2), 18-22
- https://doi.org/10.1053/sonc.2002.32749
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Survival Benefit of High-Dose Therapy in Poor-Risk Aggressive Non-Hodgkin’s Lymphoma: Final Analysis of the Prospective LNH87–2 Protocol—A Groupe d’Etude des Lymphomes de l’Adulte StudyJournal of Clinical Oncology, 2000
- Cost-minimization analysis of CHOP, fludarabine and rituximab for the treatment of relapsed indolent B-cell non-Hodgkin's lymphoma in the U.K.British Journal of Haematology, 1999
- New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project.Journal of Clinical Oncology, 1998
- Apoptosis of Malignant Human B Cells by Ligation of CD20 With Monoclonal AntibodiesBlood, 1998
- Effect of age on the characteristics and clinical behavior of non-Hodgkin's lymphoma patientsAnnals of Oncology, 1997
- A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's LymphomaBlood, 1997
- Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy.Journal of Clinical Oncology, 1995
- Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma.Journal of Clinical Oncology, 1995
- Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20Blood, 1994
- A Predictive Model for Aggressive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993